Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Inventory: 2017-2025

Historic Inventory for Ptc Therapeutics (PTCT) over the last 9 years, with Sep 2025 value amounting to $52.7 million.

  • Ptc Therapeutics' Inventory rose 47.71% to $52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.7 million, marking a year-over-year increase of 47.71%. This contributed to the annual value of $23.2 million for FY2024, which is 24.15% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Inventory stood at $52.7 million, which was up 54.69% from $34.1 million recorded in Q2 2025.
  • Ptc Therapeutics' Inventory's 5-year high stood at $52.7 million during Q3 2025, with a 5-year trough of $14.8 million in Q3 2022.
  • In the last 3 years, Ptc Therapeutics' Inventory had a median value of $31.8 million in 2024 and averaged $32.2 million.
  • Its Inventory has fluctuated over the past 5 years, first spiked by 141.37% in 2023, then decreased by 27.89% in 2025.
  • Ptc Therapeutics' Inventory (Quarterly) stood at $15.9 million in 2021, then soared by 37.54% to $21.8 million in 2022, then soared by 40.21% to $30.6 million in 2023, then fell by 24.15% to $23.2 million in 2024, then soared by 47.71% to $52.7 million in 2025.
  • Its Inventory was $52.7 million in Q3 2025, compared to $34.1 million in Q2 2025 and $21.7 million in Q1 2025.